Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 2;7(1):86.
doi: 10.1038/s41572-021-00321-x.

Idiopathic inflammatory myopathies

Affiliations
Review

Idiopathic inflammatory myopathies

Ingrid E Lundberg et al. Nat Rev Dis Primers. .

Abstract

Idiopathic inflammatory myopathies (IIM), also known as myositis, are a heterogeneous group of autoimmune disorders with varying clinical manifestations, treatment responses and prognoses. Muscle weakness is usually the classical clinical manifestation but other organs can be affected, including the skin, joints, lungs, heart and gastrointestinal tract, and they can even result in the predominant manifestations, supporting that IIM are systemic inflammatory disorders. Different myositis-specific auto-antibodies have been identified and, on the basis of clinical, histopathological and serological features, IIM can be classified into several subgroups - dermatomyositis (including amyopathic dermatomyositis), antisynthetase syndrome, immune-mediated necrotizing myopathy, inclusion body myositis, polymyositis and overlap myositis. The prognoses, treatment responses and organ manifestations vary among these groups, implicating different pathophysiological mechanisms in each subtype. A deeper understanding of the molecular pathways underlying the pathogenesis and identifying the auto-antigens of the immune reactions in these subgroups is crucial to improving outcomes. New, more homogeneous subgroups defined by auto-antibodies may help define disease mechanisms and will also be important in future clinical trials for the development of targeted therapies and in identifying biomarkers to guide treatment decisions for the individual patient.

PubMed Disclaimer

Similar articles

Cited by

References

    1. McHugh, N. J. & Tansley, S. L. Autoantibodies in myositis. Nat. Rev. Rheumatol. 14, 290–302 (2018). An up-to-date comprehensive review on auto-antibodies detected in idiopathic inflammatory myopathies. - PubMed - PMC
    1. Betteridge, Z. et al. Frequency, mutual exclusivity and clinical associations of myositis autoantibodies in a combined European cohort of idiopathic inflammatory myopathy patients. J. Autoimmun. 101, 48–55 (2019). - PubMed - PMC
    1. Walton, J. N. Some diseases of muscle. Lancet 1, 447–452 (1964). - PubMed - PMC
    1. Hoogendijk, J. E. et al. 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscul. Disord. 14, 337–345 (2004). - PubMed - PMC
    1. Loarce-Martos, J., Lilleker, J. B., Parker, M., McHugh, N. & Chinoy, H. Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre. Rheumatology 60, 3398–3403 (2021). - PubMed - PMC

Publication types

LinkOut - more resources